vs
好事达（ALL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
好事达的季度营收约是Revvity的1.2倍（$922.0M vs $772.1M），好事达净利率更高（266.6% vs 12.7%，领先253.9%），好事达同比增速更快（7.2% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs -75.8%）
好事达集团是面向美国、加拿大市场的综合性保险服务商，提供财产险、意外险及其他保险产品。旗下设好事达保险、保障服务、健康福利、到期财产责任险四大板块，主营私人乘用车险、房屋保险，亦覆盖摩托车、房车、越野车等特种车险及各类个人保险产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ALL vs RVTY — 直观对比
营收规模更大
ALL
是对方的1.2倍
$772.1M
营收增速更快
ALL
高出1.4%
5.9%
净利率更高
ALL
高出253.9%
12.7%
两年增速更快
RVTY
近两年复合增速
-75.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $922.0M | $772.1M |
| 净利润 | $2.5B | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -1400.3% | 14.5% |
| 净利率 | 266.6% | 12.7% |
| 营收同比 | 7.2% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $9.25 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALLRVTY
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | $772.1M | ||
| Q3 25 | $17.3B | $698.9M | ||
| Q2 25 | $16.6B | $720.3M | ||
| Q1 25 | $16.5B | $664.8M | ||
| Q4 24 | $16.5B | $729.4M | ||
| Q3 24 | $16.6B | $684.0M | ||
| Q2 24 | $15.7B | $691.7M |
净利润ALLRVTY
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | $98.4M | ||
| Q3 25 | $3.7B | $46.7M | ||
| Q2 25 | $2.1B | $53.9M | ||
| Q1 25 | $595.0M | $42.2M | ||
| Q4 24 | $1.9B | $94.6M | ||
| Q3 24 | $1.2B | $94.4M | ||
| Q2 24 | $331.0M | $55.4M |
毛利率ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ALLRVTY
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% |
净利率ALLRVTY
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | 12.7% | ||
| Q3 25 | 21.7% | 6.7% | ||
| Q2 25 | 12.7% | 7.5% | ||
| Q1 25 | 3.6% | 6.4% | ||
| Q4 24 | 11.7% | 13.0% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 2.1% | 8.0% |
每股收益（稀释后）ALLRVTY
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $0.86 | ||
| Q3 25 | $13.95 | $0.40 | ||
| Q2 25 | $7.76 | $0.46 | ||
| Q1 25 | $2.11 | $0.35 | ||
| Q4 24 | $7.07 | $0.77 | ||
| Q3 24 | $4.33 | $0.77 | ||
| Q2 24 | $1.13 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $31.6B | $7.3B |
| 总资产 | $124.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $919.9M | ||
| Q3 25 | $8.7B | $931.4M | ||
| Q2 25 | $9.6B | $991.8M | ||
| Q1 25 | $6.5B | $1.1B | ||
| Q4 24 | $4.5B | $1.2B | ||
| Q3 24 | $7.0B | $1.2B | ||
| Q2 24 | $5.3B | $2.0B |
总债务ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.1B | — | ||
| Q2 24 | $8.1B | — |
股东权益ALLRVTY
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $7.3B | ||
| Q3 25 | $27.5B | $7.4B | ||
| Q2 25 | $24.0B | $7.6B | ||
| Q1 25 | $22.1B | $7.6B | ||
| Q4 24 | $21.4B | $7.7B | ||
| Q3 24 | $20.9B | $7.9B | ||
| Q2 24 | $18.6B | $7.9B |
总资产ALLRVTY
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $12.2B | ||
| Q3 25 | $120.4B | $12.1B | ||
| Q2 25 | $115.9B | $12.4B | ||
| Q1 25 | $115.2B | $12.4B | ||
| Q4 24 | $111.6B | $12.4B | ||
| Q3 24 | $113.7B | $12.8B | ||
| Q2 24 | $108.4B | $13.4B |
负债/权益比ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.43× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $182.0M | ||
| Q3 25 | $3.3B | $138.5M | ||
| Q2 25 | $1.9B | $134.3M | ||
| Q1 25 | $2.0B | $128.2M | ||
| Q4 24 | $1.7B | $174.2M | ||
| Q3 24 | $3.2B | $147.9M | ||
| Q2 24 | $2.4B | $158.6M |
自由现金流ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $161.8M | ||
| Q3 25 | $3.2B | $120.0M | ||
| Q2 25 | $1.9B | $115.5M | ||
| Q1 25 | $1.9B | $112.2M | ||
| Q4 24 | $1.7B | $149.8M | ||
| Q3 24 | $3.1B | $125.6M | ||
| Q2 24 | $2.3B | $136.6M |
自由现金流率ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 21.0% | ||
| Q3 25 | 18.8% | 17.2% | ||
| Q2 25 | 11.3% | 16.0% | ||
| Q1 25 | 11.4% | 16.9% | ||
| Q4 24 | 10.0% | 20.5% | ||
| Q3 24 | 18.9% | 18.4% | ||
| Q2 24 | 14.7% | 19.7% |
资本支出强度ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | 0.3% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% |
现金转化率ALLRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | 1.85× | ||
| Q3 25 | 0.88× | 2.97× | ||
| Q2 25 | 0.89× | 2.49× | ||
| Q1 25 | 3.30× | 3.03× | ||
| Q4 24 | 0.88× | 1.84× | ||
| Q3 24 | 2.69× | 1.57× | ||
| Q2 24 | 7.13× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALL
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
